Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has nominated it as a development candidate.
MarketBeat Week in Review – 7/15 - 7/19Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next
Positive News is Driving This Cancer Drug Maker’s Stock HigherIDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
IDEAYA Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 1/24IDEAYA Biosciences, Inc. (
NASDAQIDYA) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 0.7% on the day to $25.75.
IDEAYA Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 1/19IDEAYA Biosciences, Inc. (
NASDAQIDYA) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 0.7% on the day to $25.75.
Ideaya Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 5/11IDEAYA Biosciences, Inc. (
NASDAQIDYA) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -4.37% on the day to $21.46.
IDEAYA Biosciences Inc. (NASDAQ: IDYA) Leading the Way in Monday Trading Based on Percentage GainIDEAYA Biosciences, Inc. (
NASDAQIDYA) is one of today’s top gainers. The company’s shares are currently up 25.79% on the day to $18.78.
IDEAYA Biosciences Inc. (NASDAQ: IDYA) Featured in Virtual Coverage of the 34th Annual Roth ConferenceIDEAYA Biosciences (
NASDAQIDYA) is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality — which represents an emerging class of precision medicine targets. For more information, visit the company’s website at www.IDEAYABio.com .
